Category: MS Research Study and Reports

Hydroxychloroquine for Primary Progressive Multiple Sclerosis

  Abstract Objective: Primary progressive multiple sclerosis (PPMS) does not respond well to immunomodulatory or immunosuppressive treatment. Chronic activation of microglia…

Stuart Schlossman

Alarming COVID study indicates long-term loss of gray matter and other brain tissue

 By Michael Greenwood, M.Sc.          Jun 18 2021 There has been extensive evidence of brain-related pathologies associated with COVID-19…

Stuart Schlossman

Multiple Sclerosis Linked to Infection in Adolescence

September 7, 2021 Summary:  A new study links viral infections including mononucleosis and pneumonia experienced during adolescence with an increased risk…

Stuart Schlossman

BTK Inhibitor Reduces New Lesions in Relapsing Multiple Sclerosis

 Tolebrutinib may hold promise for progressive MS, too by Judy George, Senior Staff Writer, MedPage Today September 3, 2021    Tolebrutinib, a…

Stuart Schlossman

Overcoming Obstacles to Promote Repair in Multiple Sclerosis

Tue, August 24, 2021, 1:21 PM·8 min read Study points to a new promising therapy against toxic blood leaks in…

Stuart Schlossman

Tolebrutinib Shows Dose-Dependent MS Lesion Reduction in Phase 2b Trial

 August 26, 2021    Marco Meglio The results support continued development of tolebrutinib 60 mg in phase 3 trials for MS,…

Stuart Schlossman

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis

 Marcus W Koch 1 2, Jop P Mostert 3, Jerry S Wolinsky 4, Fred D Lublin 5, Bernard Uitdehaag 6, Gary R Cutter 7 Affiliations expand PMID: 34433679   DOI: 10.1212/WNL.0000000000012690 Abstract Background: Clinical trials in…

Stuart Schlossman

BioNTech Vaccine Treats MS in Mice Without Dampening Immune System

  BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against myelin — delayed…

Stuart Schlossman

BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial

 August 20, 2021        – Marco Meglio NeurologyLive, August 2021, Volume 4, Issue 4 The agent’s safety profile has been studied in…

Stuart Schlossman

6-Week Dosing of Natalizumab Effective, May Reduce PML Risk

August 3, 2021 –   Abby Reinhard  Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates…

Stuart Schlossman

Categories

Latest Blog Posts